DEVICE, DRUG EXPORT CERTIFICATE APPLICATION FEES PLANNED BY FDA
This article was originally published in The Gray Sheet
Executive Summary
DEVICE, DRUG EXPORT CERTIFICATE APPLICATION FEES PLANNED BY FDA, according to a compliance policy guide on agency export policy released Sept. 7. FDA says in a same-day Federal Register notice announcing availability of the document that for products such as devices and drugs that fall under its jurisdiction, the agency intends to provide export certification "with the anticipation of achieving full cost recovery by charging the requester a fee based on the actual expenses incurred." The agency says it will carry out export certification services "either itself or by third parties under FDA oversight."
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.